Micell Technologies' MiStent SES Launched in Europe

February 4, 2015—Micell Technologies, Inc. announced the commercial availability in Europe of the MiStent SES, a sirolimus-eluting absorbable polymer coronary stent system. 

Micell’s distribution partner, Stentys, plans a controlled launch in Western Europe followed by a full commercial launch for the second half of 2015 in selected countries within Europe, the Middle East, Southeast Asia, and Latin America. Stentys, which is headquartered in in Paris, France, will be the exclusive distributor of the MiStent SES in all world markets except the United States, Canada, China, South Korea, and Japan.  

According to the company, MiStent SES is designed to optimize healing in patients with coronary artery disease. The rapidly absorbable coating of the MiStent SES is intended to precisely and consistently allow for local drug delivery and limit the duration of polymer exposure, thereby potentially reducing the safety risks associated with current commercially available drug-eluting stents.

Using sirolimus and the polymer PLGA (polymer polylactic-co-glycolic acid), Micell’s supercritical fluid technology allows the controlled drug/polymer coating to be applied to a bare-metal stent. The MiStent SES utilizes a thin-strut cobalt chromium coronary stent system, which has demonstrated favorable results in deliverability, conformability, and flexibility.

Micell, based in Durham, North Carolina, advised that it is expanding its manufacturing capabilities through its partner, Surgical Technologies, Inc., which is based in St. Paul, Minnesota.